两种不同BRAF抗体检测甲状腺微小乳头状癌BRAF^V600E突变蛋白的免疫组化研究  

Immunohistochemical study of BRAF^V600E mutation protein detected by two different BRAF antibodies

作　　者：禹乐 陈淑敏 王旭洲[1,3] 孟加榕 余英豪 黄仲庆 YU Le;CHEN Shumin;WANG Xuzhou;MENG Jiarong;YU Yinghao;HUANG Zhongqing(Department of Pathology, No.909 Hospital, Joint Service Support Unit, Zhangzhou 363000,China)

机构地区：[1]联勤保障部队第909医院病理科,福建漳州363000 [2]漳州卫生职业学院病理学教研室,363000 [3]联勤保障部队第900医院病理科,350025

出　　处：《临床肿瘤学杂志》2020年第11期988-992,共5页Chinese Clinical Oncology

基　　金：福建省教育厅资助项目(JAT160909);南京军区联勤第十八分部青年培育资助项目(18FBQN2015008);漳州卫生职业学院院本课题资助项目(ZYZ201606)。

摘　　要：目的探讨采用不同抗体的免疫组化法检测甲状腺微小乳头状癌(PTMC)BRAF突变蛋白的表达情况及其临床应用价值。方法收集2010年11月至2015年1月100例PTMC患者,其中接受特异性VE1抗体检测BRAF蛋白74例,F-7抗体检测BRAF蛋白99例。同时与实时荧光定量PCR(qPCR)法检测BRAF V600E突变的结果进行对比。结果VE1抗体检测结果显示,BRAF蛋白的阳性表达率为43.2%(32/74);qPCR法检测BRAF^V600E的突变率为52.7%(39/74)。VE1抗体免疫组化法与qPCR法检测一致者63例(85.1%),两种方法的吻合程度具有一致性(Kappa=0.705,P=0.000)。VE1抗体检测BRAF蛋白表达的灵敏度为76.9%,特异度为94.3%。F-7抗体检测结果显示,BRAF蛋白的阳性表达率为74.8%(74/99);qPCR检测BRAF^V600E的突变率为53.5%(53/99)。F-7抗体与qPCR检测一致者66例(66.7%),两种方法的吻合程度具有一致性(Kappa=11.729,P=0.001)。F-7抗体检测BRAF蛋白表达的灵敏度为88.7%,特异度为41.3%。结论免疫组化法是筛选PTMC BRAF蛋白的一种可行方法,特异性VE1抗体比F-7抗体更具有临床应用价值。Objective To investigate the expression of BRAF protein in papillary thyroid microcarcinoma(PTMC)by immunohistochemistry with different antibodies and its clinical application value.Methods From November 2010 to January 2015,100 cases of PTMC were enrolled,among whom specific VE1 antibody and F-7 antibody were used to detect BRAF mutation protein in 74 cases and 99 cases of PTMC,respectively.Meanwhile,real-time fluorescence quantitative PCR(qPCR)was used for comparison.Results VE1 antibody test showed that the positive rate of BRAF protein was 43.2%(32/74),and the mutant rate of BRAF^V600E was 52.7%(39/74)by qPCR.The concordance rate between VE1 antibody and qPCR was 85.1%(63/74,Kappa=0.705,P=0.000).VE1 antibody had a sensitivity of 76.9%and specificity of 94.3%for detecting the mutation.F-7 antibody test showed that the positive rate of BRAF protein was 74.8%(74/99),and the mutant rate of BRAF^V600E was 53.5%(53/99)by qPCR.The concordance rate between F-7 antibody and qPCR was 66.7%(74/99,Kappa=11.729,P=0.001).The F-7 antibody had a sensitivity of 88.7%and specificity of 41.3%for detecting the mutation.Conclusion Immunohistochemistry is a feasible method to screen BRAF^V600E protein of PTMC,and specific VE1 antibody has more clinical value than F-7 antibody.

关 键 词：甲状腺微小乳头状癌(PTMC) 免疫组织化学 VE1抗体 F-7抗体 BRAF^V600E突变 

分 类 号：R739.91[医药卫生—肿瘤]